A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010)
第3相
完了
NCT04199104
| 対象疾患 | Head and Neck Squamous Cell Carcinoma |
|---|
| 相 | 第3相 |
|---|
| スポンサー | Merck Sharp & Dohme LLC |
|---|
| ステータス | 完了 |
|---|
| 参加者数 | 511 名 |
|---|
| 介入（薬剤） | Lenvatinib, Pembrolizumab |
|---|
| 開始日 | 2020年2月5日 |
|---|
| 完了日 | 2023年5月30日 |
|---|
| 結果公開日 | 2024年7月16日 |
|---|
概要
This is a study of pembrolizumab (MK-3475) with or without lenvatinib (E7080/MK-7902) as a first line intervention in a PD-L1 selected population with participants with recurrent or metastatic head and neck squamous cell carcinoma. Hypotheses include: * Pembrolizumab + lenvatinib is superior to pembrolizumab + placebo with respect to Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by blinded independent central review (BICR). * Pembrolizumab + lenvatinib is superior to pembrolizumab + placebo with respect to Progression Free Survival (PFS) per RECIST 1.1 as assessed by BICR. * Pembrolizumab + lenvatinib is superior to pembrolizumab + placebo with respect to overall survival (OS).
Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)
Up to ~ 37 months · Percentage of participants
| Pembrolizumab + Lenvatinib | 46.9 Percentage of participants |
|---|
| Pembrolizumab + Placebo | 27.5 Percentage of participants |
|---|
| p-value | 0.0000019 |
|---|
| point estimate | 19.3 (95% CI 11.2–27.3) |
|---|
Progression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR).
Up to ~ 37 months · Months
| Pembrolizumab + Lenvatinib | 7.0 Months |
|---|
| Pembrolizumab + Placebo | 2.8 Months |
|---|
| p-value | 0.0001129 |
|---|
| Hazard Ratio (HR) | 0.68 (95% CI 0.55–0.83) |
|---|
Overall Survival (OS)
Up to ~ 37 months · Months
| Pembrolizumab + Lenvatinib | 15.0 Months |
|---|
| Pembrolizumab + Placebo | 17.9 Months |
|---|
| p-value | 0.8819584 |
|---|
| Hazard Ratio (HR) | 1.15 (95% CI 0.91–1.45) |
|---|
BENITIONS で見る
ClinicalTrials.gov の原文を見る
すべての治験
このページは ClinicalTrials.gov の公開データをまとめたものです。医学的助言ではなく、投資助言でもありません。必ず専門医にご相談ください。